CARsgen Therapeutics Holdings Ltd (02171), a leading biotech company, witnessed a significant surge of 5.98% in its stock price during the intraday trading session on Tuesday.
This rally can be attributed to the company's announcement of positive topline results from a pivotal Phase II clinical trial in China for its Claudin18.2 CAR-T cell therapy, SATRI-CEL. The study met its primary endpoint of improved progression-free survival (PFS), showcasing the therapy's potential efficacy in treating gastric cancer and gastroesophageal junction adenocarcinoma.
Encouraged by these promising results, CARsgen anticipates submitting a New Drug Application (NDA) to the National Medical Products Administration (NMPA) in China during the first half of 2025, paving the way for potential market approval and commercialization of SATRI-CEL.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.